The Latest Breaking News from AstraZeneca Plc

Pfizer is also facing off with collaborators Sanofi and AstraZeneca Plc to develop prevention for dangerous RSV infections in newborns, a market that could reach $1.5 billion.

While rising inflation and the Fed’s rate hikes are expected to keep the stock market volatile in the near term, large-cap stocks could help survive. Therefore, fundamentally sound large-cap stocks, Coca-Cola (KO) and AstraZeneca (AZN), which are currently trading under $100, might be solid additions to your portfolio. Keep reading.

Following a year of solid growth in 2022, leading pharma company AstraZeneca’s (AZN) robust pipeline and recent launches look promising. Moreover, its strong fundamentals should enable the stock to deliver solid returns this year. So, AZN could be an ideal buy. Keep reading.

The pharma industry has experienced tremendous growth in recent years. The industry should continue to grow, driven by the growing market for personalized medicine and e-pharmacies. Hence, pharma stocks Pfizer (PFE), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and Zoetis (ZTS) might be worth buying for the long term. Also, these companies…

Expectations of the economy avoiding a recession have been rising amid the still-tight labor market and improving consumer sentiments. However, while uncertainties remain, quality stocks Walmart (WMT), AstraZeneca (AZN), and LSI Industries (LYTS), which are Strong Buy-rated in our proprietary system, could be ideal additions to boost your portfolios. Keep…

Receding inflationary pressure and the Fed’s smaller rate hike have raised investor optimism. However, amid additional rate hike fears and associated volatilities, investors could scoop up quality stocks Johnson & Johnson (JNJ), Coca-Cola (KO), and AstraZeneca (AZN) that could help them build wealth in the market. Read on….

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….

The pharma industry is well-placed to benefit from the rise of chronic diseases and an aging population. Moreover, given the stable demand for medicines, the industry is relatively unaffected by macroeconomic uncertainty. Therefore, it could be wise for investors to buy fundamentally strong pharma stocks AstraZeneca (AZN) and Novartis (NVS).…

The pharmaceutical industry is well-positioned to witness substantial growth, driven by the prevalence of chronic diseases, the aging population, and increased healthcare spending. Given the industry’s promising growth prospects, we think it could be wise to invest in fundamentally sound pharmaceutical stocks Johnson & Johnson (JNJ), Merck & Co (MRK),…

Easing inflation and the Fed’s indication of slowing the pace of interest rate hikes are raising investors’ sentiments. Moreover, the November job report came in better than expected. While uncertainties remain, we think quality stocks Pfizer (PFE), AstraZeneca PLC (AZN), Carrier Global (CARR), J. Jill (JILL), and Lifeway Foods (LWAY)…

Intensive innovation, breakthrough developments, and growing investments should help the biotech industry witness solid growth over the next decade. And given the sector’s reputation as a safe haven amid economic turmoil, it could be wise for investors to buy and hold fundamentally solid biotech stocks Amgen (AMGN) and AstraZeneca (AZN)…